中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
2期
188-191
,共4页
急性脑梗死%丁苯酞软胶囊%神经功能
急性腦梗死%丁苯酞軟膠囊%神經功能
급성뇌경사%정분태연효낭%신경공능
Acute cerebral infarction%Butylphthalide soft capsule%Nervous function
目的 观察丁苯酞软胶囊治疗急性脑梗死的临床效果及安全性.方法 将浙江省义乌市中心医院的91例急性脑梗死患者完全随机分为对照组(44例)与观察组(47例).对照组给予阿司匹林治疗,根据病情给予甘露醇及甘油果糖脱水降颅内压、维持水电解质平衡、降糖、降压、降脂等常规治疗,观察组在常规治疗基础上加用丁苯酞软胶囊0.2g空腹口服,每日3次,2周为1个疗程,共治疗4周.在治疗前和治疗后2、4周,采用欧洲脑卒中量表分别进行神经功能(ESS)评分和日常生活能力(Barthel)评分,并评价其疗效和用药安全性.结果 2组治疗2、4周后的ESS评分与治疗前比较[对照组:(47±6)、(51±10)分比(37±7)分;观察组:(50±7)、(64±8)分比(35±7)分],差异均有统计学意义(均P＜0.05).治疗4周后,观察组ESS评分与对照组比较,差异有统计学意义(P＜0.05).2组治疗2、4周后的Barthel评分与治疗前比较[对照组:(40±10)、(56 ±8)分比(30±6)分;观察组:(45±19)、(66±9)分比(31±16)分],差异均有统计学意义(均P＜0.05).治疗4周后,观察组Barthel评分与对照组比较,差异有统计学意义(P＜0.05).观察组总有效率为85.1％(40/47),对照组总有效率为65.9％ (29/44),差异有统计学意义(P＜0.05).结论 丁苯酞软胶囊治疗急性脑梗死疗效确切,安全性良好.
目的 觀察丁苯酞軟膠囊治療急性腦梗死的臨床效果及安全性.方法 將浙江省義烏市中心醫院的91例急性腦梗死患者完全隨機分為對照組(44例)與觀察組(47例).對照組給予阿司匹林治療,根據病情給予甘露醇及甘油果糖脫水降顱內壓、維持水電解質平衡、降糖、降壓、降脂等常規治療,觀察組在常規治療基礎上加用丁苯酞軟膠囊0.2g空腹口服,每日3次,2週為1箇療程,共治療4週.在治療前和治療後2、4週,採用歐洲腦卒中量錶分彆進行神經功能(ESS)評分和日常生活能力(Barthel)評分,併評價其療效和用藥安全性.結果 2組治療2、4週後的ESS評分與治療前比較[對照組:(47±6)、(51±10)分比(37±7)分;觀察組:(50±7)、(64±8)分比(35±7)分],差異均有統計學意義(均P＜0.05).治療4週後,觀察組ESS評分與對照組比較,差異有統計學意義(P＜0.05).2組治療2、4週後的Barthel評分與治療前比較[對照組:(40±10)、(56 ±8)分比(30±6)分;觀察組:(45±19)、(66±9)分比(31±16)分],差異均有統計學意義(均P＜0.05).治療4週後,觀察組Barthel評分與對照組比較,差異有統計學意義(P＜0.05).觀察組總有效率為85.1％(40/47),對照組總有效率為65.9％ (29/44),差異有統計學意義(P＜0.05).結論 丁苯酞軟膠囊治療急性腦梗死療效確切,安全性良好.
목적 관찰정분태연효낭치료급성뇌경사적림상효과급안전성.방법 장절강성의오시중심의원적91례급성뇌경사환자완전수궤분위대조조(44례)여관찰조(47례).대조조급여아사필림치료,근거병정급여감로순급감유과당탈수강로내압、유지수전해질평형、강당、강압、강지등상규치료,관찰조재상규치료기출상가용정분태연효낭0.2g공복구복,매일3차,2주위1개료정,공치료4주.재치료전화치료후2、4주,채용구주뇌졸중량표분별진행신경공능(ESS)평분화일상생활능력(Barthel)평분,병평개기료효화용약안전성.결과 2조치료2、4주후적ESS평분여치료전비교[대조조:(47±6)、(51±10)분비(37±7)분;관찰조:(50±7)、(64±8)분비(35±7)분],차이균유통계학의의(균P＜0.05).치료4주후,관찰조ESS평분여대조조비교,차이유통계학의의(P＜0.05).2조치료2、4주후적Barthel평분여치료전비교[대조조:(40±10)、(56 ±8)분비(30±6)분;관찰조:(45±19)、(66±9)분비(31±16)분],차이균유통계학의의(균P＜0.05).치료4주후,관찰조Barthel평분여대조조비교,차이유통계학의의(P＜0.05).관찰조총유효솔위85.1％(40/47),대조조총유효솔위65.9％ (29/44),차이유통계학의의(P＜0.05).결론 정분태연효낭치료급성뇌경사료효학절,안전성량호.
Objective To observe the clinical efficacy and safety of butylphthalide soft capsules in the treatment of acute cerebral infarction.Methods A total of 91 patients with acute cerebral infarction were divided into two groups:the control group (n =44) and the observation group (n =47).The control group was given aspirin therapy,according to the condition of given in the conventional treatment for reducing intracranial pressure by using mannitol and glycerol fructose dehydration.The observation group was given conventional treatment combined with butylphthalide soft capsules.Results Before treatment and 2,4 weeks of after treatment,the European stroke scale (ESS) and activity of daily living (Barthel) score were applied to evaluate the clinical efficacy and drug safety.Two groups had different ESS scores after treatment[control group:(47 ± 6),(51 ± 10) scores vs (37 ± 7) scores ; the observation group:(50 ± 7),(64 ± 8) scores vs (35 ± 7) scores],differences were statistically significant (P ＜ 0.05).Mter 4 weeks treatment,ESS score of the observation group compared with the control group,the difference was statistically significant (P ＜ 0.05).Barthel index of two groups after treatment of 2,4 weeks compared with before treatment [control group:(40 ± 10),(56 ± 8) scores vs (30 ± 6) scores; observation group:(45 ± 19),(66 ±9) scores vs (31 ± 16) scores],the differences were statistically significant (P ＜0.05).After 4 weeks treatment,the observation group' s Barthel index compared with the control group,the difference was statistically significant (P ＜ 0.05).The total effective rate was 85.1％ (40/47) in the observation group,and 65.9％ (29/44) in the control group,the difference was statistically significant (P ＜ 0.05).Conclusion Butylphthalide soft capsule has a good curative effect and good security in the treatment of acute cerebral infarction.
